Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Targeting Sickle Cell Disease

Targeting Sickle Cell Disease

FromTargeting the Toughest Diseases


Targeting Sickle Cell Disease

FromTargeting the Toughest Diseases

ratings:
Length:
15 minutes
Released:
Oct 24, 2022
Format:
Podcast episode

Description

Terri Booker’s body burns with pain. She’s one of the 100,000 Americans living with sickle cell disease – a blood disorder that can cause severe pain, organ failure, and even premature death. The genetic condition came about to protect against malaria. Dr. William Hobbs leads clinical development for sickle cell disease at Vertex – their investigational research into sickle cell disease uses cutting-edge technology. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals. Featured guests:Terri Booker is an attorney and sickle cell advocate based in Philadelphia, Pennsylvania.Dr. Isaac Odame  is the Haematology Section Head in the Division of Haematology/Oncology and the Medical Director of the Global Sickle Cell Disease Network at the Centre for Global Child Health at The Hospital for Sick Children.Dr. David Altshuler is the Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals. William Hobbs is a Vice President leading clinical development into hematology at Vertex Pharmaceuticals.Dr. William Hobbs is the VP- Clinical Development, Hematology at Vertex Pharmaceuticals.Read more about Vertex's approach to targeting sickle cell disease  
Released:
Oct 24, 2022
Format:
Podcast episode

Titles in the series (7)

Targeting the Toughest Diseases looks at some of humanity’s most challenging diseases and how Vertex Pharmaceuticals, a Boston-based biotech company, is using innovative tools, methods, and a unique philosophy to search for treatments and cures. Produced by Bloomberg Media Studios and Vertex Pharmaceuticals.